Invitation to QBiotics Virtual Investor Briefing

BRISBANE, 27 August 2026

QBiotics Group Limited (QBiotics) is pleased to invite investors to join a live-streamed investor briefing on Wednesday, 9 September 2026 at 5:00pm AEST.

During the briefing, attendees will hear from members of the QBiotics Board and management team, including:

  • Simon Pollard - Non-Executive Chairman
  • Dr Victoria Gordon - Executive Director, Chief Strategy Officer and Co-Founder
  • Ebru Davidson - Interim CEO and Managing Director, and
  • Andrew Craig - Global Investor Relations Officer.

The team will provide an update on QBiotics' clinical-stage development programs, including the recently announced Phase II Head and Neck cancer trial results for tigilanol tiglate. The presentation will also cover progress across the Company's broader pipeline and recently opened Prospectus Offer.

A Q&A session will follow the presentation. Participants are encouraged to submit questions in advance to communications@qbiotics.com for discussion during the session. Questions should be submitted by 5:00pm AEST on Monday, 7 September 2026.

Participants can register via the following link:

https://us02web.zoom.us/webinar/register/WN_PCuKjrsJTJy2Ke_OOX8HGQ

Once registered, participants will receive a confirmation email with details on how to access the investor briefing webinar.

The QBiotics team looks forward to welcoming those who can join us.

 

—ends—

 

For further information, please visit our website at qbiotics.com or contact:

FURTHER INFORMATION
EBRU DAVIDSON, INTERIM CEO & MANAGING DIRECTOR
communications@qbiotics.com

or

MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774

 
ABOUT QBIOTICS

QBiotics Group Limited (QBiotics) is an Australian public unlisted biotechnology company, advancing two clinical-stage, differentiated, small molecule programmes derived from our epoxytigliane platform.

QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, is demonstrating strong efficacy and safety in human clinical Phase II studies. Tigilanol tiglate data has been reported from a Phase II clinical trial in soft tissue sarcoma and a Phase II clinical trial in head and neck cancer. These studies demonstrated objective response rates of 82% and 78%, respectively, in injected tumours with most adverse events consistent with the expected local mode of action of the drug and translational research validating immunological responses. Impressive efficacy and safety outcomes have been achieved in a range of other tumour types under Compassionate Use. No Maximum Tolerated Dose (MTD) was declared in a Phase I safety study and efficacy was reported in nine different tumour types. QBiotics is in planning to implement a Phase II trial in breast cancer in partnership with Unicancer, the French Federation of cancer centres and is currently exploring the treatment of visceral tumours by tigilanol tiglate in a preclinical study.

QBiotics’ second programme is a topically applied regenerative wound therapy EBC-1013 that accelerates wound infill and closure, minimises scarring, and provides local antimicrobial activity. This drug candidate has demonstrated impressive safety and efficacy against chronic and acute wounds and burns in veterinary studies. It is currently in a human Phase I clinical study treating Venous Leg Ulcers.

Patent coverage for tigilanol tiglate and EBC-1013 is broad and Chemistry, Manufacturing and Controls (CMC) is mature, with commercial supply of tigilanol tiglate secured.

QBiotics employs a capital-efficient model that integrates its EcoLogic™ discovery technology with phenotypic screening and early validation in veterinary disease models. This approach enables rapid identification of biologically active molecules, early demonstration of efficacy and safety in complex disease settings in the veterinary environment, and meaningful de-risking prior to human clinical development. Product development is led by an experienced team and complemented by internationally recognised Key Opinion Leaders on our Clinical and Scientific Advisory Boards, who bring deep expertise in oncology, wound healing, antimicrobials, small molecule chemistry and translational drug development.

QBiotics’ business strategy is to advance therapeutic programmes with the potential to address multiple high-value indications through to Phase II proof-of-concept in human clinical studies, and then pursue strategic partnering to accelerate late-stage development and commercialisation.

For more, head to: QBiotics.com or LinkedIn